Is Arcus Biosciences, Inc. (RCUS) a Buy, Sell, or Hold?
NYSE : RCUS
Arcus Biosciences, Inc.
$28.42 USD
-$1.31 (-4.41%)
- Volume
- 874.08K
- Average Volume
- 1.23M
- Market Capitalization
- $3.57B
- P/E Ratio
- -8.97
- Dividend Yield
- 0.00%
- Price Target
- $35.00
- Year High
- $31.74
- Year Low
- $8.84
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.04
Company Overview
NYSE
Terry J. Rosen
Biotechnology
Healthcare
RCUS
601
US
USD
Liquidity Metrics
0.22
4.04
4.04
0.96
0.00
Sales & Valuation
$247M
15.15
6.80
-7.31
-3.90
Profitability
-$3.29
-$353M
-156.36%
-156.36%
-68.97%
-37.01%
P/E Metrics
-8.97
-0.39
-0.39
Analyst Price Target & Rating
$35.00
$47.00
$22.00
1/5
18 Analysts
-18.80%
Financial Health Scores
1.41
1/9
$635M
$997M
$473M
-$339M
Key Metrics (TTM)
$3.49B
14.77
-10.57
4.04
-68.97%
-49.69%
-10.35%
-13.68%
-2023 days
Company Executives
| Name | Title |
|---|---|
| Holli Kolkey | Vice President of Corporate Communications |
| Carolyn C. Tang | General Counsel & Corporate Secretary |
| Pia Eaves | Vice President of Investor Relations & Strategy |
| Richard A. Markus | Chief Medical Officer |
| Alexander Azoy | Chief Accounting Officer |
| Jennifer A. Jarrett | Advisor |
| Robert C. Goeltz | Principal Financial Officer & Chief Financial Officer |
| K. Christopher Garcia | Co-Founder & Member of Scientific Advisory Board |
| Juan Carlos Jaen | Co- Founder & President |
| Terry J. Rosen | Co-Founder, Chairman & Chief Executive Officer |
| Jonathan Yingling | Chief Scientific Officer |
Poll Results
No votes yet today — be the first to share your view!
About Arcus Biosciences, Inc. (NYSE:RCUS) Stock
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clini ... cal trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
2026-07-23 11:36:25
Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.
2026-07-22 16:35:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus's investigational small-molecule HIF-2α inhibitor, in combination with tivozan.
2026-07-22 16:30:00
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne.
2026-07-22 16:30:00
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne.
2026-07-21 16:05:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Wednesday, August 5th, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline updates for the quarter ended June 30th, 20.
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?
2026-07-20 14:45:26
HC Wainwright raised its price forecast for Arcus Biosciences Inc. (NASDAQ:RCUS), citing the aggressive push into 1L clear cell renal cell carcinoma (ccRCC) development.
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run
2026-07-13 19:09:17
This sale was executed under a Rule 10b5-1 plan following a 203% one-year surge.
Arcus Biosciences Announces New Employment Inducement Grants
2026-07-09 16:35:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted five new employee options to purchase a total of 16,060 shares of the Company's common stock at an exercise price per share of $30.26, which was the.
Frequently Asked Questions
-
What is the current Arcus Biosciences, Inc. (RCUS) stock price?
-
Arcus Biosciences, Inc.(NYSE:RCUS) stock price is $28.42 in the last trading session. During the trading session, RCUS stock reached the peak price of $31.735 while $8.84 was the lowest point it dropped to. The percentage change in RCUS stock occurred in the recent session was --4.41% while the dollar amount for the price change in RCUS stock was -$1.31.
-
RCUS's industry and sector of operation?
-
The NYSE listed RCUS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RCUS?
-
Holli Kolkey | Vice President of Corporate Communications
Carolyn C. Tang | General Counsel & Corporate Secretary
Pia Eaves | Vice President of Investor Relations & Strategy
Richard A. Markus | Chief Medical Officer
Alexander Azoy | Chief Accounting Officer -
How many employees does RCUS have?
-
Number of RCUS employees currently stands at 601. RCUS operates from 3928 Point Eden Way, Hayward, CA 94545, US.
-
Link for RCUS official website?
-
Official Website of RCUS is: https://arcusbio.com
-
How do I contact RCUS?
-
RCUS could be contacted at phone #510 694 6200 and can also be accessed through its website. RCUS operates from 3928 Point Eden Way, Hayward, CA 94545, US.
-
How many shares of RCUS are traded daily?
-
The average number of RCUS shares traded daily for last 3 months was 1.23M.
-
What is the market cap of RCUS currently?
-
The market value of RCUS currently stands at $3.57B with its latest stock price at $28.42